Is VEEV a good stock to buy? We came across a bullish thesis on Veeva Systems Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on VEEV. Veeva Systems Inc.’s share was trading at $167.95 as of April 17th. VEEV’s trailing and forward P/E were 30.87 and 18.94, respectively according to Yahoo Finance.
Wichy/Shutterstock.com
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. VEEV operates at the center of a durable, non-cyclical digital transformation within the global life sciences industry, positioning itself as the core operating system for critical workflows spanning clinical development, regulatory compliance, and commercial operations.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The company benefits from strong secular tailwinds, including rising pharmaceutical R&D spending driven by aging populations, increasing pressure to accelerate drug development timelines, and rapid adoption of AI-driven solutions, all of which reinforce demand for Veeva’s integrated cloud platform.
Despite a temporary slowdown in FY2024, Veeva has re-accelerated growth, delivering 16.2% revenue expansion in FY2025 with improving revenue quality as subscription services now comprise roughly 84% of total revenue. The SaaS model continues to drive meaningful operating leverage, with significant margin expansion expected as the company transitions away from Salesforce, eliminating approximately $80 million in annual royalty payments by 2030.
Veeva’s dominant industry position, including approximately 80% market share in life sciences CRM and deep penetration across top pharmaceutical companies, creates high switching costs and a powerful competitive moat reinforced by regulatory complexity. Financially, the company maintains a fortress balance sheet with over $6.5 billion in net cash and strong free cash flow generation, enabling continued investment and strategic flexibility.
While near-term concerns around CRM competition and client renewals have pressured valuation, this appears largely sentiment-driven rather than fundamental. With multiple catalysts, including CRM migration success, AI monetization, and continued R&D platform expansion, Veeva presents a compelling long-term opportunity with favorable risk-reward skew and potential for sustained compounding growth.
